Earn-out structures in European biotech deals: what Recall surfaces
Across 184 anonymised acquisition agreements with European biotech targets, what milestone types, efforts standards and dispute mechanisms look like, and what Review does with that.
Across 184 anonymised acquisition agreements with European biotech targets, what milestone types, efforts standards and dispute mechanisms look like, and what Review does with that.
A dismissed flag costs a reviewer forty-one seconds. That is the small number. The larger one is what happens to the next three flags.
Zero retention means we cannot read the contracts our model reviews. So how do we know it is improving? A method built on synthetic drafts, in-tenant scoring and a panel of lawyers who disagree.
Our in-house model: what it was trained on, what it was not, how it was evaluated against the models we previously routed to, and where it still falls short.
Simulation models venues, not named arbitrators. This note sets out what a corpus of published awards actually supports, where selection bias defeats it, and why we stopped short.
What 480 anonymised 2024 technology SPAs in our index say about material adverse change drafting: carve-out counts, cyber language, and the slow exit of the pandemic clause.
Accept rate rewards timid redlines. Here is the four-part measure we use instead, the sample behind it, and the places where it still misleads us.
A bilingual contract that differs between its two language versions is a dispute waiting for a tribunal. Here is how we test for parity, what the test catches, and what it still misses.
Time saved is the easiest number to inflate. Here is how we define first-pass review time, who we measure, what we exclude and where the measurement still misleads.